RxDoctor Payments Data

Suzette Rivera Macmurray, MD

Gastroenterology · San Juan, PRNPI 1982678744

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,838 of the $7,566 with a category attached, or 63.9%. AbbVie accounts for 88.1% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2021 at $2,961 and has fallen 56.9% since, to $1,277 in 2025.

$7,566in general payments, 2019–2025

Across 43 payments — averaging $175.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$7K
  • Olympus Latin America, Inc.$147
  • Gilead$125
  • Takeda Pharmaceuticals U.S.A., Inc.$120
  • E.r. Squibb & Sons, L.L.C.$119
  • Johnson & Johnson$99
  • plus $289 from 4 others

What the payments were for

  • Consulting fees$4,83864%
  • Food & beverage$2,63035%
  • Education$991%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie34$6,667
Olympus Latin America, Inc.1$147
Gilead1$125
Takeda Pharmaceuticals U.S.A., Inc.1$120
E.r. Squibb & Sons, L.L.C.1$119
Johnson & Johnson1$99
Boston Scientific1$99
Merck1$98
Madrigal Pharmaceuticals1$77
PBG Puerto Rico LLC1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,566 in reported general payments places this provider in the 85th percentile of 198 gastroenterology providers in Puerto Rico.

See all gastroenterology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$84,450
Medicare patients
230
Services billed
574

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab24$665,919
Mesalamine44$28,000
Sucralfate87$17,530
Mesalamine DrMesalamine25$16,454
SuprepSodium, Potassium,mag Sulfates140$16,408
Lansoprazole397$6,091
Naloxone Hcl366$4,391
SutabSod Sulf/Pot Chloride/Mag Sulf23$3,845
Famotidine357$3,513
Dexlansoprazole DrDexlansoprazole14$3,387
Tetracycline Hcl13$1,323
Pantoprazole Sodium59$685
Dicyclomine Hcl52$646
Esomeprazole Magnesium31$615
Midazolam Hcl204$506

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$99$665,91924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 198 gastroenterology providers in Puerto Rico.

Other gastroenterology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →